echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Differentiated layout, domestic CAR-Ts compete to appear at the 2022 ASCO annual meeting

    Differentiated layout, domestic CAR-Ts compete to appear at the 2022 ASCO annual meeting

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    foreword

    On May 26, 2022, the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract was released online, in which a number of domestic CAR-T cell therapy products were unveiled, with product indications covering hematological tumors and solid tumors, and target selection Diversified, with different technical routes, the overall presentation is a 3D three-dimensional differentiated layout , showing the strong strength of the domestic CAR-T R&D pipeli.


    Indications cover hematological tumors and solid tumors, with diversified target selection and different technical routes, showing a 3D three-dimensional differentiated layout as a whole

    relapsed/refractory multiple myeloma

    relapsed/refractory multiple myeloma

    In the treatment of relapsed/refractory multiple myeloma, Yuanqi Bio's OriCAR-017 product adopts the second-generation CAR molecular design targeting GPRC5D, and adds its unique Ori element on this bas.


    Compared with the new target of GPRC5D, the CAR-T combined with the old target BCMA/CD19 is also invaluable in the treatment of RR.


    solid tumor

    solid tumor

    Claudin12 (CLDN12) is a promising therapeutic target whose expression is usually restricted to the tight junction of the gastric mucosa, but is frequently overexpressed in gastric/gastro-esophageal junction (G/GEJ) cance.


    Nanjing Kaidi Biotech has constructed a novel bispecific CAR-T cell (KD-496), which can recognize both NKG2D ligand and CLDN12, and shows excellent antitumor efficacy and safety in vitro and in vivo , where the in vivo data were derived from the patient's PDX mod.


    CAR-T cell therapy has shown significant clinical efficacy in hematological malignancies, but limited efficacy in solid tumo.


    Malignant pleural/peritoneal mesothelioma (MPM) is an aggressive cancer characterized by poor response to therapy and poor survival, and PD-1-mediated immunosuppression has been implicated in T cell exhaustion and dysfunction in solid tumo.


    Relapsed/refractory B-cell acute leukemia

    Relapsed/refractory B-cell acute leukemia

    CD19-targeting CAR-T cell therapy products have shown very surprising efficacy in r/r B-ALL, but some life-threatening side effects, especially high-grade cytokine release syndrome (CRS) and immune effector cells are related Neurotoxicity syndrome (ICANS) limits its widespread u.


    The results show that the PrimeCAR platform can prepare CAR-T cells in a very short time, and has a high Tscm ratio, which has good safety and shows good efficacy in the treatment of r/r B-ALL at very low dos.


    Cytokine release syndrome (CRS) has been a life-threatening toxic side effect since the FDA approved the first CD19 CAR-T cell therapy product (Kymriah) for the treatment of patients with r/r B-ALL, severely limiting its therapeutic potenti.


    relapsed/refractory T-cell acute lymphoblastic leukemia

    relapsed/refractory T-cell acute lymphoblastic leukemia

    The team of Pan Jing from Beijing Boren Hospital updated the clinical data of donor-derived CD7 CAR.


    Donor-derived CD7 CAR-T is very effective in the treatment of relapsed/refractory T-cell acute leukemia, but some patients will develop graft-versus-host disease (GVH.


    Reference: https://conferenc.


    Reference: https://conferenc.
    as.
    org/am/abstracts-posters
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.